Attorney Discusses Cosmetic Trespasses On Drug Turf Leading To FDA Action
This article was originally published in The Rose Sheet
Executive Summary
The line that divides drugs from personal care is "fuzzy," but companies can begin to understand what marketing claims are acceptable to FDA by learning from the mistakes of others, Ivan Wasserman, partner at Manatt, Phelps & Phillips, suggests
You may also be interested in...
Nip + Fab Launches At Target Featuring Bust Fix “Boob Lift In A Tube”
Nip + Fab’s new 18-SKU product line at Target features Bust Fix, which purports to “visibly plump, smooth and firm the skin around the bust and décolleté.” The serum includes CellActive-FORM, a plant-based complex that “supports the natural process of lipid deposition.”
In Brief
FTC Vs. "Worthless" Eco-Certifications
In Brief
FTC Vs. "Worthless" Eco-Certifications